By Josh White
Date: Thursday 04 Sep 2025
(Sharecast News) - Oxford BioDynamics said on Thursday that interim results from its ongoing FDA-registered PROWES trial demonstrated that its EpiSwitch CiRT test had a significant impact on treatment decisions for cancer patients receiving immune checkpoint inhibitors.
By Josh White
Date: Wednesday 13 Aug 2025
(Sharecast News) - Oxford BioDynamics announced a collaboration with Google Cloud on Wednesday, to accelerate the development and deployment of its cloud-based analytical framework for precision medicine.
By Josh White
Date: Friday 09 May 2025
(Sharecast News) - Oxford BioDynamics announced on Friday that its Oxford-based laboratory had been accredited by the UK Accreditation Service (UKAS) as a clinical facility under ISO 15189, enabling it to process 'EpiSwitch' clinical tests in the UK.
Currency | UK Pounds |
Share Price | 0.48p |
Change Today | 0.005p |
% Change | -1.04 % |
52 Week High | 3.79 |
52 Week Low | 0.26 |
Volume | 13,354,451 |
Shares Issued | 1,957.58m |
Market Cap | £9.30m |
Value | ![]() |
---|
Price Trend | ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
12:24 | 869 @ 0.48p |
12:08 | 33,922 @ 0.45p |
12:07 | 2,691 @ 0.45p |
11:29 | 781,667 @ 0.47p |
11:19 | 330,000 @ 0.48p |
You are here: research